Shares of Cellectis SA (NASDAQ:CLLS) saw strong trading volume on Tuesday . 105,183 shares traded hands during mid-day trading, an increase of 19% from the previous session’s volume of 88,115 shares.The stock last traded at $24.43 and had previously closed at $24.39.

A number of analysts have recently commented on the stock. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Cellectis SA in a research report on Monday, June 20th. Jefferies Group reissued a “buy” rating on shares of Cellectis SA in a research report on Friday, August 5th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $44.17.

The stock’s market cap is $871.26 million. The stock has a 50 day moving average of $26.57 and a 200-day moving average of $27.71.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/cellectis-sa-clls-sees-large-volume-increase.html

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Apex Capital Management purchased a new position in Cellectis SA during the first quarter valued at about $254,000. HighTower Advisors LLC raised its position in Cellectis SA by 0.3% in the second quarter. HighTower Advisors LLC now owns 13,440 shares of the company’s stock valued at $357,000 after buying an additional 40 shares during the last quarter. GAM Holding AG raised its position in Cellectis SA by 61.7% in the second quarter. GAM Holding AG now owns 15,220 shares of the company’s stock valued at $405,000 after buying an additional 5,810 shares during the last quarter. Fiera Capital Corp purchased a new position in Cellectis SA during the second quarter valued at about $452,000. Finally, Picton Mahoney Asset Management raised its position in Cellectis SA by 40.7% in the first quarter. Picton Mahoney Asset Management now owns 26,800 shares of the company’s stock valued at $737,000 after buying an additional 7,750 shares during the last quarter.

Cellectis SA Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

5 Day Chart for NASDAQ:CLLS

Receive News & Ratings for Cellectis SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis SA and related companies with MarketBeat.com's FREE daily email newsletter.